Cullinan Therapeutics (CGEM) Operating Expenses (2020 - 2026)

Cullinan Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $53.7 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 2.36% year-over-year to $53.7 million; the TTM figure through Mar 2026 stood at $240.3 million (up 15.04% YoY), while the FY2025 annual figure was $241.6 million, up 22.71% from the prior year.
• Operating Expenses for Q1 2026 stood at $53.7 million, down from $55.3 million in the prior quarter.
• The five-year high for Operating Expenses was $75.8 million in Q2 2025, with the low at $29.8 million in Q3 2022.
• The 5-year median for Operating Expenses is $48.9 million (2024), against an average of $47.9 million.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 123.48% in 2022, then plunged 31.5% in 2024.
• Cullinan Therapeutics' Operating Expenses stood at $32.6 million in 2022, then soared by 39.49% to $45.5 million in 2023, then grew by 21.02% to $55.0 million in 2024, then gained by 0.38% to $55.3 million in 2025, then retreated by 2.83% to $53.7 million in 2026.
• Business Quant data shows CGEM's Operating Expenses at $53.7 million in Q1 2026, $55.3 million in Q4 2025, and $55.6 million in Q3 2025.